Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-27

Clinical Trial Update: A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating safety, pharmacodynamics, and pharmacokinetics of a single dose of SYN023 with licensed rabies vaccines in human rabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SYN023 (SYN023)

Snippet

Sponsor: Synermore Biologics Co., Ltd. | Conditions: Human Rabies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-27